Powers of the vertex cover ideals

We describe a combinatorial condition on a graph which guarantees that all powers of its vertex cover ideal are componentwise linear. Then motivated by Eagon and Reiner's Theorem we study whether all powers of the vertex cover ideal of a Cohen-Macaulay graph have linear free resolutions. After giving a complete characterization of Cohen-Macaulay cactus graphs (i.e., connected graphs in which each edge belongs to at most one cycle) we show that all powers of their vertex cover ideals have linear resolutions

An Assessment of Recent and Future Temperature Change over the Sichuan Basin, China, using CMIP5 Climate Models

The Sichuan basin is one of the most densely populated regions of China, making the area particularly vulnerable to the adverse impacts associated with future climate change. As such, climate models are important for understanding regional and local impacts of climate change and variability, like heat stress and drought. In this study, climate models from phase 5 of the Coupled Model Intercomparison Project (CMIP5) are validated over the Sichuan basin by evaluating how well each model can capture the phase, amplitude, and variability of the regionally observed mean, maximum, and minimum temperature between 1979 and 2005. The results reveal that the majority of the models do not capture the basic spatial pattern and observed means, trends, and probability distribution functions. In particular, mean and minimum temperatures are underestimated, especially during the winter, resulting in biases exceeding −3°C. Models that reasonably represent the complex basin topography are found to generally have lower biases overall. The five most skillful climate models with respect to the regional climate of the Sichuan basin are selected to explore twenty-first-century temperature projections for the region. Under the CMIP5 high-emission future climate change scenario, representative concentration pathway 8.5 (RCP8.5), the temperatures are projected to increase by approximately 4°C (with an average warming rate of +0.72°C decade−1), with the greatest warming located over the central plains of the Sichuan basin, by 2100. Moreover, the frequency of extreme months (where mean temperature exceeds 28°C) is shown to increase in the twenty-first century at a faster rate compared to the twentieth century.Funding for this research was provided by the Engineering and Physical Sciences Research Council (EPSRC) as part of the Low Carbon Climate-Responsive Heating and Cooling of Cities (LoHCool) project (EP/N009797/1)

Lessons learned from EVOLVE for the planning of future global randomized trials in chronic kidney disease

The effect of the calcimimetic cinacalcet on cardiovascular disease in patients undergoing hemodialysis with secondary hyperparathyroidism (sHPT) was evaluated in the EVOLVE trial. This was the largest (in size) and longest (in duration) randomized controlled clinical trial undertaken in this population. During planning, execution, analysis and reporting of the trial many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints (particularly heart failure and severe unremitting HPT), importance of age for optimal stratification at randomization, use of unadjusted and adjusted intention-to-treat analysis for the primary outcome, how to respond to a lower than predicted event rate during the trial, development of a pre-specified analytic plan that accounted for non-adherence and for co-interventions that diminished the power of the trial to observe a treatment effect, determination of the credibility of a subgroup effect, use of adverse effects database to investigate rare diseases, collection of blood for biomarker measurement not designated prior to trial initiation, and interpretation of the benefits to harms ratio for individual patients. It is likely that many of these issues will arise in planning of future trials in chronic kidney disease

Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Patients with severely decreased glomerular filtration rate (GFR) (i.e., chronic kidney disease [CKD] G4+) are at increased risk for kidney failure, cardiovascular disease (CVD) events (including heart failure), and death. However, little is known about the variability of outcomes and optimal therapeutic strategies, including initiation of kidney replacement therapy (KRT). Kidney Disease: Improving Global Outcomes (KDIGO) organized a Controversies Conference with an international expert group in December 2016 to address this gap in knowledge. In collaboration with the CKD Prognosis Consortium (CKD-PC) a global meta-analysis of cohort studies (n = 264,515 individuals with CKD G4+) was conducted to better understand the timing of clinical outcomes in patients with CKD G4+ and risk factors for different outcomes. The results confirmed the prognostic value of traditional CVD risk factors in individuals with severely decreased GFR, although the risk estimates vary for kidney and CVD outcomes. A 2- and 4-year model of the probability and timing of kidney failure requiring KRT was also developed. The implications of these findings for patient management were discussed in the context of published evidence under 4 key themes: management of CKD G4+, diagnostic and therapeutic challenges of heart failure, shared decision-making, and optimization of clinical trials in CKD G4+ patients. Participants concluded that variable prognosis of patients with advanced CKD mandates individualized, risk-based management, factoring in competing risks and patient preferences

Transcatheter Aortic Valve Implantation in Dialysis Patients

Background/Aims: Transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option for high-risk patients. However, dialysis patients were excluded from all previous studies. The aim of this study is to compare the outcomes of TAVI for dialysis patients with those for patients with chronic kidney disease (CKD) stages 3 and 4 and to compare TAVI with open surgery in dialysis patients. Methods: Part I: comparison of 10 patients on chronic hemodialysis with 116 patients with non-dialysis-dependent CKD undergoing TAVI. Part II: comparison of transcatheter (n = 15) with open surgical (n = 24) aortic valve replacement in dialysis patients. Results: Part I: dialysis patients were significantly younger (72.3 vs. 82.0 years; p < 0.01). Hospital stay was significantly longer in dialysis patients (21.8 vs. 12.1 days; p = 0.01). Overall 30-day mortality was 3.17%, with no deaths among dialysis patients. Six-month survival rates were similar (log-rank p = 0.935). Part II: patient age was comparable (66.5 vs. 69.5 years; p = 0.42). Patients in the surgical group tended to stay longer in hospital than TAVI patients (29.5 vs. 22.5 days; p = 0.35). Conclusion: TAVI is a safe procedure in patients on chronic hemodialysis. Until new data become available, we find no compelling reason to refuse these patients TAVI. Copyright (C) 2012 S. Karger AG, Base

Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease.

Cardiovascular disease is a prevalent and prognostically important comorbidity among patients with kidney disease, and individuals with kidney disease make up a sizeable proportion (30%-60%) of patients with cardiovascular disease. However, several systematic reviews of cardiovascular trials have observed that patients with kidney disease, particularly those with advanced kidney disease, are often excluded from trial participation. Thus, currently available trial data for cardiovascular interventions in patients with kidney disease may be insufficient to make recommendations on the optimal approach for many therapies. The Kidney Health Initiative, a public-private partnership between the American Society of Nephrology and the US Food and Drug Administration, convened a multidisciplinary, international work group and hosted a stakeholder workshop intended to understand and develop strategies for overcoming the challenges with involving patients with kidney disease in cardiovascular clinical trials, with a particular focus on those with advanced disease. These efforts considered perspectives from stakeholders, including academia, industry, contract research organizations, regulatory agencies, patients, and care partners. This article outlines the key challenges and potential solutions discussed during the workshop centered on the following areas for improvement: building the business case, re-examining study design and implementation, and changing the clinical trial culture in nephrology. Regulatory and financial incentives could serve to mitigate financial concerns with involving patients with kidney disease in cardiovascular trials. Concerns that their inclusion could affect efficacy or safety results could be addressed through thoughtful approaches to study design and risk mitigation strategies. Finally, there is a need for closer collaboration between nephrologists and cardiologists and systemic change within the nephrology community such that participation of patients with kidney disease in clinical trials is prioritized. Ultimately, greater participation of patients with kidney disease in cardiovascular trials will help build the evidence base to guide optimal management of cardiovascular disease for this population

Aging and Holography

Aging phenomena are examples of `non-equilibrium criticality' and can be exemplified by systems with Galilean and scaling symmetries but no time translation invariance. We realize aging holographically using a deformation of a non-relativistic version of gauge/gravity duality. Correlation functions of scalar operators are computed using holographic real-time techniques, and agree with field theory expectations. At least in this setup, general aging phenomena are reproduced holographically by complexifying the bulk space-time geometry, even in Lorentzian signature.Comment: 1 pdf figur

Universal time-dependent deformations of Schrodinger geometry

We investigate universal time-dependent exact deformations of Schrodinger geometry. We present 1) scale invariant but non-conformal deformation, 2) non-conformal but scale invariant deformation, and 3) both scale and conformal invariant deformation. All these solutions are universal in the sense that we could embed them in any supergravity constructions of the Schrodinger invariant geometry. We give a field theory interpretation of our time-dependent solutions. In particular, we argue that any time-dependent chemical potential can be treated exactly in our gravity dual approach.Comment: 24 pages, v2: references adde

Non-perturbative effects and the refined topological string

The partition function of ABJM theory on the three-sphere has non-perturbative corrections due to membrane instantons in the M-theory dual. We show that the full series of membrane instanton corrections is completely determined by the refined topological string on the Calabi-Yau manifold known as local P1xP1, in the Nekrasov-Shatashvili limit. Our result can be interpreted as a first-principles derivation of the full series of non-perturbative effects for the closed topological string on this Calabi-Yau background. Based on this, we make a proposal for the non-perturbative free energy of topological strings on general, local Calabi-Yau manifolds.Comment: 38 pages, 5 figure